File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0014-2999(02)02762-0
- Scopus: eid_2-s2.0-0037419530
- PMID: 12504786
- WOS: WOS:000180303700009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Attenuated arterial and venous constriction in conscious rats with streptozotocin-induced diabetes
Title | Attenuated arterial and venous constriction in conscious rats with streptozotocin-induced diabetes |
---|---|
Authors | |
Keywords | Angiotensin Capacitance Circulatory filling pressure Diabetes Mean Noradrenaline Vasoconstriction |
Issue Date | 2003 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar |
Citation | European Journal Of Pharmacology, 2003, v. 458 n. 3, p. 299-304 How to Cite? |
Abstract | We examined if arterial or venous constriction is impaired in early diabetes. Dose-pressor and mean circulatory filling pressure (index of venous tone) response curves to noradrenaline and angiotensin II were constructed in four groups of conscious, instrumented, Wistar rats pretreated with streptozotocin (60 mg/kg i.v.) or vehicle at 2 weeks prior to the study. Rats with diabetes, relative to controls, had increased ED 50 (reduced potency) for the pressor (2.5-fold of control) and mean circulatory filling pressure (4.3-fold of control) response to noradrenaline, as well as reduced maximum pressor response (efficacy) to noradrenaline (diabetic, 74±8 mm Hg; control, 96±5 mm Hg). Diabetic rats also had reduced potency (ED 50, 5-fold of control) of the pressor response to angiotensin II; however, maximum pressor response and dose-mean circulatory filling pressure curve to angiotensin II were similar in both groups. Therefore, arterial and venous constrictions are impaired at an early phase of type I diabetes. © 2002 Elsevier Science B.V. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/171293 |
ISSN | 2023 Impact Factor: 4.2 2023 SCImago Journal Rankings: 1.055 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheng, X | en_US |
dc.contributor.author | Leung, SWS | en_US |
dc.contributor.author | Lim, SL | en_US |
dc.contributor.author | Pang, CCY | en_US |
dc.date.accessioned | 2012-10-30T06:13:14Z | - |
dc.date.available | 2012-10-30T06:13:14Z | - |
dc.date.issued | 2003 | en_US |
dc.identifier.citation | European Journal Of Pharmacology, 2003, v. 458 n. 3, p. 299-304 | en_US |
dc.identifier.issn | 0014-2999 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171293 | - |
dc.description.abstract | We examined if arterial or venous constriction is impaired in early diabetes. Dose-pressor and mean circulatory filling pressure (index of venous tone) response curves to noradrenaline and angiotensin II were constructed in four groups of conscious, instrumented, Wistar rats pretreated with streptozotocin (60 mg/kg i.v.) or vehicle at 2 weeks prior to the study. Rats with diabetes, relative to controls, had increased ED 50 (reduced potency) for the pressor (2.5-fold of control) and mean circulatory filling pressure (4.3-fold of control) response to noradrenaline, as well as reduced maximum pressor response (efficacy) to noradrenaline (diabetic, 74±8 mm Hg; control, 96±5 mm Hg). Diabetic rats also had reduced potency (ED 50, 5-fold of control) of the pressor response to angiotensin II; however, maximum pressor response and dose-mean circulatory filling pressure curve to angiotensin II were similar in both groups. Therefore, arterial and venous constrictions are impaired at an early phase of type I diabetes. © 2002 Elsevier Science B.V. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar | en_US |
dc.relation.ispartof | European Journal of Pharmacology | en_US |
dc.subject | Angiotensin | - |
dc.subject | Capacitance | - |
dc.subject | Circulatory filling pressure | - |
dc.subject | Diabetes | - |
dc.subject | Mean | - |
dc.subject | Noradrenaline | - |
dc.subject | Vasoconstriction | - |
dc.subject.mesh | Angiotensin Ii - Pharmacology | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Arteries - Drug Effects - Physiopathology | en_US |
dc.subject.mesh | Blood Pressure - Drug Effects | en_US |
dc.subject.mesh | Consciousness | en_US |
dc.subject.mesh | Diabetes Mellitus, Experimental - Physiopathology | en_US |
dc.subject.mesh | Dose-Response Relationship, Drug | en_US |
dc.subject.mesh | Heart Rate - Drug Effects | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Norepinephrine - Pharmacology | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, Sprague-Dawley | en_US |
dc.subject.mesh | Vasoconstriction - Drug Effects - Physiology | en_US |
dc.subject.mesh | Veins - Drug Effects - Physiopathology | en_US |
dc.title | Attenuated arterial and venous constriction in conscious rats with streptozotocin-induced diabetes | en_US |
dc.type | Article | en_US |
dc.identifier.email | Leung, SWS:swsleung@hku.hk | en_US |
dc.identifier.authority | Leung, SWS=rp00235 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0014-2999(02)02762-0 | en_US |
dc.identifier.pmid | 12504786 | - |
dc.identifier.scopus | eid_2-s2.0-0037419530 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0037419530&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 458 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 299 | en_US |
dc.identifier.epage | 304 | en_US |
dc.identifier.isi | WOS:000180303700009 | - |
dc.publisher.place | Netherlands | en_US |
dc.identifier.scopusauthorid | Cheng, X=37044433300 | en_US |
dc.identifier.scopusauthorid | Leung, SWS=24540419500 | en_US |
dc.identifier.scopusauthorid | Lim, SL=7404080728 | en_US |
dc.identifier.scopusauthorid | Pang, CCY=7201425219 | en_US |
dc.identifier.issnl | 0014-2999 | - |